Eyenovia/EYEN

$0.84

2.84%
-
1D1W1MYTD1YMAX

About Eyenovia

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Ticker

EYEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Tsontcho Ianchulev

Employees

57

Headquarters

New york, United States
Website
eyenovia.com

Eyenovia Metrics

BasicAdvanced
$39M
Market cap
-
P/E ratio
-$0.66
EPS
1.73
Beta
-
Dividend rate
$39M
1.72582
$3.97
$0.50
1.4M
2.173
2.161
99.535
158.757
-15.14%
-91.15%
-207.83%
-119.11%
10,370.4
3.904
5.716
20.93%
-87.63%

What the Analysts think about Eyenovia

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
741.67% upside
High $12.00
Low $3.20
$0.84
Current price
$7.07
Average price target

Eyenovia Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
NaN%
Net income
-$7.9M
8.22%
Profit margin
0%
NaN%

Eyenovia Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.86%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.16
-$0.18
-$0.18
-
Expected
-$0.19
-$0.18
-$0.18
-$0.18
-$0.17
Surprise
-21.26%
-8.57%
0%
2.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Eyenovia stock?

Eyenovia (EYEN) has a market cap of $39M as of May 15, 2024.

What is the P/E ratio for Eyenovia stock?

The price to earnings (P/E) ratio for Eyenovia (EYEN) stock is 0 as of May 15, 2024.

Does Eyenovia stock pay dividends?

No, Eyenovia (EYEN) stock does not pay dividends to its shareholders as of May 15, 2024.

When is the next Eyenovia dividend payment date?

Eyenovia (EYEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Eyenovia?

Eyenovia (EYEN) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Eyenovia stock price target?

The target price for Eyenovia (EYEN) stock is $7.07, which is 751.81% above the current price of $0.83. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Eyenovia stock

Buy or sell Eyenovia stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing